Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy in Patients with cN0, T1 or T2 Invasive Breast Cancer By Ogkologos - January 14, 2025 722 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INSEMA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... March 24, 2021 How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy March 3, 2021 Women in science: Cancer research pioneers – part 2 January 25, 2023 Listening to Patient Narratives June 9, 2020 Load more HOT NEWS Aiming to Prevent New Cancer Cases, ESMO Calls for Increased Minimum... Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... Beloved Kindergarten Teacher Who Inspired Her Community Dies of Breast Cancer... ΚΑΡΚΙΝΟΣ ΤΟΥ ΠΡΟΣΤΑΤΗ
